CMBA
GTHX

C.M. Bidwell & Associates’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

C.M. Bidwell & Associates’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,800
Closed -$34K – 484
2018
Q4 		$34K Buy
+1,800
New +$67.4K 0.04% 270

Other funds holding GTHX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

C.M. Bidwell & Associates's GTHX Position: Q1 2019 in Review

C.M. Bidwell & Associates sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q1 2019, closing a stake of 1,800 shares — an estimated $34K sold.

C.M. Bidwell & Associates first reported a position in GTHX in Q4 2018 and held it in 1 quarter. The position peaked at $34K in Q4 2018. 93 funds tracked by Wall St. Rank hold GTHX as of Q1 2019.

  • C.M. Bidwell & Associates reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 1,800 G1 Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $34K.
  • C.M. Bidwell & Associates first reported a position in G1 Therapeutics, Inc. Common Stock in Q4 2018 and held it in 1 quarter.
  • C.M. Bidwell & Associates's G1 Therapeutics, Inc. Common Stock position peaked at $34K in Q4 2018.
  • 93 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q1 2019.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2019, filed 15 May 2019.